Chronic Kidney Disease stem cell therapy — your questions answered (2026)
About stem cell therapy for Chronic Kidney Disease
Chronic kidney disease (CKD) is persistent kidney damage or reduced filtration caused by diabetes, hypertension, immune, genetic, obstructive and other disorders. Cell and exosome research explores inflammatory, vascular and repair mechanisms, but a laboratory signal does not establish restored nephron number, delayed kidney failure or avoidance of dialysis or transplantation.
The evidence for Chronic Kidney Disease
Evidence is investigational and must match CKD cause and stage, exact product, route, comparator and clinically meaningful kidney and cardiovascular outcomes. The NIDDK CKD management guide emphasises blood-pressure and diabetes control, prescribed medicines, monitoring, nutrition and preparation for kidney replacement therapy when needed. An experimental infusion must not delay those measures.
Itemise nephrology assessment, product, administration, laboratory and cardiovascular monitoring, medicines, travel, follow-up, complication care and any dialysis or transplant planning. Do not compare a commercial infusion price with long-term CKD care without accounting for evidence and the risk of delay.
Can stem cells repair kidneys?
Cell therapy for Chronic Kidney Disease may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.
Which CKD stage qualifies?
Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.
Does it replace dialysis?
Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.
EU cost?
The partner-published indicative range for an Chronic Kidney Disease programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Chronic Kidney Disease (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
← Back to Chronic Kidney Disease overview · Chronic Kidney Disease cost →